Analyzing genomic and immune data from 14,246 patients, researchers found nearly 58% of younger patients had guideline-recommended actionable mutations, compared with about 45% of patients age 55 and older.
Analyzing genomic and immune data from 14,246 patients, researchers found nearly 58% of younger patients had guideline-recommended actionable mutations, compared with about 45% of patients age 55 and older.